New leadership at the American Cancer society: What Shane Jacobson’s appointment Means for the Future of Cancer Research & Advocacy
The fight against cancer is about to get a new leader. On July 25th, 2025, the American Cancer Society (ACS) and its advocacy arm, the American cancer Society Cancer Action Network (ACS CAN), announced Shane Jacobson as their new CEO, effective August 12th. This appointment marks a pivotal moment for both organizations,signaling a renewed focus on stakeholder engagement and fundraising to maximize impact. But what does this change mean for you, for cancer patients, and for the future of cancer research?
Jacobson, currently the CEO of the V Foundation for Cancer Research, succeeds Dr. Wayne A. I.Frederick, who has served as interim CEO as November 2024. His background and stated priorities suggest a dynamic shift towards a more collaborative and impactful approach. Let’s delve into what you need to no about this leadership transition and its potential implications.
A Proven Leader Takes the Helm
Jacobson isn’t new to the world of cancer fundraising and advocacy.his success at the V Foundation, known for its impactful grant programs and celebrity endorsements, demonstrates a clear ability to drive resources towards critical research.He’s an Iowa State University alumnus, holding both a bachelor’s and master’s degree from the institution, and a graduate of the Harvard University Management Development Programme.
Did you Know? according to the National Cancer Institute, in 2024, there were an estimated 2,001,140 new cancer cases diagnosed in the United States. https://www.cancer.gov/about-cancer/understanding/statistics
This appointment comes at a crucial time. Cancer remains a leading cause of death worldwide, and advancements in treatment and prevention rely heavily on consistent funding and effective advocacy. Jacobson’s focus on stakeholder engagement – connecting with patients, researchers, donors, and policymakers – is a promising sign.
Key Priorities: A Roadmap for the Future
jacobson has outlined two primary organizational priorities: stakeholder engagement and fundraising. But what do these mean in practice?
Stakeholder Engagement: This involves actively listening to and collaborating with all parties involved in the fight against cancer. This includes patients and their families, the medical community, research institutions, and government officials.
elevated Fundraising: Securing increased financial support is vital for funding groundbreaking research, providing patient support services, and advocating for policies that improve cancer prevention and treatment.He also plans to establish a long-term strategic plan to ensure the ACS and ACS CAN remain relevant and impactful in a rapidly evolving landscape. This proactive approach is essential for adapting to new challenges and opportunities in cancer research and care.
Pro Tip: Want to get involved? Explore volunteer opportunities with the American Cancer Society in your local area. Even a few hours of your time can make a significant difference! https://www.cancer.org/involved/volunteer.html
Understanding the Role of the American Cancer Society & ACS CAN
It’s significant to understand the distinct, yet interconnected, roles of these two organizations. American Cancer Society (ACS): Primarily focused on research funding, patient support, and education. They provide resources for cancer prevention, detection, and treatment.
American Cancer Society Cancer Action Network (ACS CAN): The advocacy affiliate, dedicated to influencing public policy to improve cancer prevention and treatment access. They lobby for legislation that supports cancer research and patient care.
jacobson’s leadership will encompass both, fostering a unified approach to tackling cancer from all angles. This synergy is crucial for maximizing impact.
Secondary Keywords: cancer research funding, cancer advocacy, patient support services, cancer prevention, cancer treatment access.
The Impact of Recent Research & Trends
Recent breakthroughs in cancer treatment, such as immunotherapy and targeted therapies, offer hope for improved outcomes. A study published in nature Medicine in May 2025 showed promising results for a new immunotherapy combination in treating advanced melanoma. https://www.nature.com/nm/
However, disparities in cancer care persist. According to the American Cancer Society, racial and ethnic minorities often experience higher